Skip to main content

Boston Scientific Interventional Cardiology & Vascular Therapies revenue

  • BSX · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$44.34+0.32%Close 13 Nov 2026 · Market value $63.59B

Interventional Cardiology & Vascular Therapies revenue at Boston Scientific came to $1.3B for the quarter to 30 Sep 2026, up 12.2% from a year earlier.

As Boston Scientific reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 2 Nov 2026.

By quarter

$614.0MDec 2023$652.0MMar 2024$665.0MJun 2024$661.0MSep 2024$668.0MDec 2024$1.1BMar 2025$1.2BJun 2025$1.1BSep 2025$1.2BDec 2025$1.2BMar 2026$1.3BJun 2026$1.3BSep 2026
Boston Scientific Interventional Cardiology & Vascular Therapies revenue, every reported period
Period endingInterventional Cardiology & Vascular Therapies revenueChange on a yearFiled
30 Sep 2026$1.3Bup 12.2%2 Nov 2026
30 Jun 2026$1.3Bup 13.2%3 Aug 2026
31 Mar 2026$1.2Bup 10.7%1 May 2026
31 Dec 2025$1.2Bup 79.9%17 Feb 2026
30 Sep 2025$1.1Bup 71.7%3 Nov 2025
30 Jun 2025$1.2Bup 77.1%1 Aug 2025
31 Mar 2025$1.1Bup 72.4%1 May 2025
31 Dec 2024$668.0Mup 8.8%18 Feb 2025
30 Sep 2024$661.0Mup 13.4%1 Nov 2024
30 Jun 2024$665.0Mup 5.7%1 Aug 2024
31 Mar 2024$652.0Mup 10.3%1 May 2024
31 Dec 2023$614.0Mup 9.4%20 Feb 2024
30 Sep 2023$583.0Mup 6.2%1 Nov 2023
30 Jun 2023$629.0Mup 9.6%3 Aug 2023
31 Mar 2023$591.0Mup 8.6%4 May 2023
31 Dec 2022$561.0Mdown 2.4%23 Feb 2023
30 Sep 2022$549.0Mup 2.8%3 Nov 2022
30 Jun 2022$574.0Munchanged4 Aug 2022
31 Mar 2022$544.0Mup 3.4%5 May 2022
31 Dec 2021$575.0M—23 Feb 2022
30 Sep 2021$534.0M—4 Nov 2021
30 Jun 2021$574.0M—6 Aug 2021
31 Mar 2021$526.0M—6 May 2021

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Boston Scientific: Electrophysiology revenue · Endoscopy revenue · Peripheral Interventions revenue · Urology revenue · Cardiac Rhythm Management revenue · Watchman revenue · Neuromodulation revenue · Interventional Oncology & Embolization revenue · Cardiology revenue · Cardiovascular revenue · MedSurg revenue · United States revenue · Int'l revenue · Emerging Markets revenue · financial statements

Every KPI and segment of BSX, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.